Late-life depression: recognising atypical presentations in older adults

Depression in older adults: different from what you expect

Depression in older Australians is common, treatable, and consistently under-detected. It affects approximately 7–10% of community-dwelling people aged 65 and over, rising to 15–30% of those living in residential aged-care facilities. Prevalence is higher still in the context of chronic disease — around 40% in Parkinson’s disease, 30% after stroke, and 20% with dementia.

The central reason for under-detection is presentation. Older adults with depression rarely present with prominent sadness or crying. Instead, they come to general practice with fatigue, vague somatic complaints, multiple pains, cognitive slowing, loss of interest framed as “I’m just old”, early-morning waking, irritability, and quietly held hopelessness. They often deny being depressed even when asked directly. The term “masked depression” captures this pattern — the affective component is hidden under a layer of somatic and cognitive symptoms.

The stakes are high. Australian men aged 85 and over carry the highest age-specific completed-suicide rate of any demographic group — approximately four times the general-population rate per AIHW Suicide and Self-harm Monitoring — and they rarely volunteer suicidal ideation. Outdoor access to firearms in rural settings increases lethality. This is why direct, open questioning about suicidal thoughts is mandatory, not optional.

A. Core clinical — the AU general-practice framework

Screening

The Geriatric Depression Scale (GDS-15) is the recommended screening tool for older adults. Its 15 yes/no items deliberately avoid somatic questions (sleep, appetite, energy) that overlap with physical illness — making it more specific than the PHQ-9 in this population. A score of 6 or above suggests significant depression and warrants full diagnostic assessment. The GDS-5 (five items) is useful when time is very limited, such as during the 75+ Health Assessment.

The Cornell Scale for Depression in Dementia (CSDD) uses informant-based rating and is preferred in moderate-to-severe dementia when self-report is unreliable.

Assessment

Cognitive screen: Perform a MoCA (preferred — more sensitive to executive and mild cognitive impairment than the MMSE) at baseline. Late-onset depression frequently co-exists with early neurodegeneration, and “pseudodementia” — cognitive deficits driven entirely by depression that improve with treatment — is a real but increasingly understood to represent a prodromal or co-occurring dementia in many cases. Repeat the MoCA at 3–6 months after antidepressant treatment; persisting deficits warrant memory-clinic referral.

Medication review: This is mandatory. Many drugs commonly prescribed to older Australians are depressogenic or increase anticholinergic burden, which suppresses cognition and worsens mood: beta-blockers (especially propranolol), corticosteroids, opioids, anticonvulsants, and some dopaminergic agents. Use the ACB Calculator to estimate anticholinergic burden. NPS MedicineWise provides deprescribing resources.

Organic exclusion: Before attributing symptoms to depression, investigate with FBC (anaemia), UEC (sodium, renal function — SIADH risk on SSRIs, dose adjustment), TSH (hypothyroidism mimics depression closely), B12 and folate (common in elderly; metformin, PPIs, and atrophic gastritis cause depletion), calcium (hypercalcaemia — moans and psychic groans), and HbA1c. Obtain a baseline ECG before starting SSRIs, particularly in patients with known arrhythmia or QTc-prolonging polypharmacy.

Suicide risk: Ask directly, in plain language. “Have you had any thoughts of ending your life?” is not going to plant the idea — it is going to surface the thought the patient has been reluctant to raise. Document the assessment (ideation, plan, intent, access to means), apply the Stanley-Brown safety planning framework, and restrict access to firearms and medication stockpiles.

Differential diagnosis

Delirium must be excluded before any other diagnosis is pursued — acute onset, fluctuating attention, and a precipitant (infection, medication change, metabolic disturbance) point to delirium rather than depression. Prolonged grief disorder (severe yearning persisting ≥12 months after bereavement) is treated differently from depression. Bipolar disorder, though less common at first presentation in later life, requires screening for prior manic or hypomanic episodes before starting an antidepressant.

B. Evidence: antidepressants, psychological therapy, and ECT

Antidepressants

A Cochrane meta-analysis (Wilson 2013) confirms that antidepressants produce a modest but real benefit over placebo in late-life depression. The Cipriani Lancet 2018 network meta-analysis confirms efficacy across age groups.

Per eTG Psychotropic and RANZCP 2020 guidelines:

Agent	Start dose	Target range	Notes for elderly
Sertraline	25–50 mg daily	50–200 mg	Often preferred — minimal CYP interactions; check Na+ at 2 weeks
Escitalopram	5–10 mg daily	10–20 mg max	QTc-dependent; max 20 mg/day in elderly per TGA 2011 alert
Mirtazapine	7.5–15 mg nocte	15–45 mg nocte	Sedation + appetite stimulation useful for insomnia + weight loss; caution for falls
Duloxetine	30 mg daily	30–60 mg	Useful with neuropathic pain comorbidity; avoid in severe chronic kidney disease
Vortioxetine	5 mg daily	5–20 mg	Modest cognitive benefit; nausea; expensive

Avoid in elderly: TCAs (amitriptyline, dosulepin — anticholinergic burden, cardiac risk in overdose, falls); paroxetine (anticholinergic, severe discontinuation syndrome); citalopram above 20 mg/day; benzodiazepines (falls, delirium, cognitive impairment, dependence).

Psychological therapy

CBT adapted for older adults (CBT-OA), interpersonal therapy (IPT — particularly for grief and role transitions), and behavioural activation are all effective and equivalent to antidepressants for mild-to-moderate late-life depression. For moderate-to-severe depression, combined antidepressant plus psychological therapy is superior to either alone (RANZCP 2020).

Access via the Better Access scheme: Mental Health Care Plan (items 2715/2717) enables 10 psychology sessions per year. Tele-psychology is widely available and particularly useful for older adults with mobility limitations.

ECT — the most effective treatment for severe late-life depression

ECT in late-life depression is strongly evidence-based. The RANZCP 2020 guidelines endorse ECT as the treatment of choice for severe, psychotic, or treatment-refractory late-life depression. Response rates in older adults exceed 70–80%. Transient cognitive side effects — the main concern — are usually mild and resolve within weeks of completing the course. Older age and frailty are not contraindications; the anaesthetic risk is manageable with modern assessment and technique.

ECT is especially appropriate when: a patient is refusing food and fluids; suicidality is severe and immediate; psychotic features (nihilistic delusions, somatic delusions) are present; or two adequate antidepressant trials have failed.

Repetitive transcranial magnetic stimulation (rTMS) is TGA-approved and MBS-rebatable (item 14224 range) for treatment-resistant depression meeting specific criteria. It avoids anaesthesia and cognitive side effects, producing less cognitive burden than ECT but somewhat lower response rates.

C. Stepped care — from mild to refractory

Mild late-life depression: Psychoeducation, lifestyle measures (150 minutes per week of moderate aerobic exercise, Mediterranean-style diet, socialisation, sleep hygiene, sensory aids — hearing, vision), and watchful waiting with 2–4 week review. Behavioural activation is highly accessible. Antidepressant if symptoms persist beyond 4 weeks.

Moderate-to-severe late-life depression: Combined SSRI plus psychological therapy. Safety planning in place. Refer for 75+ Health Assessment (item 705) if not completed; include ACAT referral if functional decline is present. Initiate GPCCMP (items 965/967) for chronic or recurrent depression with comorbidities.

Refractory late-life depression: Switch or augment — SSRI to SNRI or mirtazapine, or consider the “California rocket fuel” combination (sertraline plus mirtazapine) under specialist guidance. Refer to old-age psychiatry (psychogeriatrician) for ECT assessment. rTMS via specialist referral. Esketamine intranasal (Spravato) is TGA-approved for treatment-resistant depression but is not PBS-listed (approximately $450 per dose private).

D. Australian operations

Medicare (MBS): The 75+ Health Assessment (item 705) mandates cognitive and depression screening — use the GDS-15. The ATSI Health Assessment (item 715) uses culturally adapted screens (RUDAS, KICA). Mental Health Care Plan (items 2715/2717) enables Better Access psychology. GPCCMP (items 965/967, replacing retired items 721/723 as of 1 July 2025) is applicable for chronic or recurrent depression as a chronic condition. Specialist case conference (items 735/739/743) supports multidisciplinary geriatric mental health review. ECG (item 11707) is rebatable for pre-SSRI baseline.

My Aged Care pathway: ACAT assessment via My Aged Care (1800 200 422) for home-care packages (Support at Home since 2025), respite, or residential care when functional decline warrants it. Carer support via Carer Gateway (1800 422 737) — carer burden and late-life depression are bidirectional.

DVA: Gold Card holders have full coverage for mental health care including psychology, psychiatry, and ECT, without needing a service-related link (Non-Liability Mental Health Care). Open Arms (1800 011 046) provides veteran-specific counselling.

Medico-legal: Driving may need to be restricted if sedation from antidepressants or cognitive impairment is significant — refer to Austroads Assessing Fitness to Drive. Capacity assessment (domain-specific; presume capacity unless clearly lacking). Arrange advance care directive, enduring power of attorney, and enduring guardian appointment while capacity is intact.

E. Special populations

Residential aged-care facility (RACF) residents: Prevalence is 15–30%. Cornell Scale for Depression in Dementia is the appropriate screening tool in moderate-to-severe dementia. Psychotropic prescribing requires notification to the Aged Care Quality and Safety Commission since 1 July 2021. Antipsychotics for BPSD (including mood-congruent psychosis in LLD) carry a black-box mortality warning in dementia — use at the lowest dose for the shortest duration, with specialist input.

ATSI Elders: Social and Emotional Wellbeing (SEWB) framework. Engage Aboriginal Mental Health Workers and Elders. 13YARN (13 92 76) provides 24/7 crisis support. Cultural grief, loss, intergenerational trauma, and isolation are specific drivers in this group.

Veterans: Higher rates of PTSD, alcohol use, and chronic pain contributing to late-life depression. DVA Gold Card and Open Arms are key pathways.

Parkinson’s disease and DLB: Depression is common and often precedes motor symptoms. Avoid antipsychotics in DLB — risk of severe neuroleptic sensitivity reaction. SSRIs are generally safe in Parkinson’s. Specialist input for the neuropsychiatric complexity.

When to escalate

Escalate urgently (ED + acute mental health team) for:

• Acute suicidality with plan, intent, or access to means
• Food and fluid refusal
• Psychotic features (nihilistic delusions, command hallucinations)
• Suspected delirium (acute onset, fluctuating consciousness — requires urgent workup)
• Severe agitation with safety risk

Refer to old-age psychiatry (psychogeriatrician) when: diagnosis is diagnostically complex (dementia overlap, bipolar uncertainty); ECT candidacy; treatment-resistant after two adequate trials; rTMS assessment required.

What this article is and is not

This article draws on the RANZCP 2020 Mood Disorders Clinical Practice Guidelines, eTG Psychotropic, the RACGP Silver Book for aged care, and key trials. It is general health information and does not create a clinician–patient relationship. Individual management decisions, including specific drug choices and referral pathways, are made with treating clinicians.

Crisis contacts: Lifeline 13 11 14 · Beyond Blue 1300 22 4636 · Suicide Call Back Service 1300 659 467 · MensLine 1300 78 99 78 · 13YARN 13 92 76

Consumer resources: Beyond Blue — older Australians · Black Dog Institute · My Aged Care · HealthDirect — Depression

---

Sources cited

1. RANZCP — 2020 Mood Disorders CPG
2. RACGP Silver Book — aged care
3. Therapeutic Guidelines (eTG) — Psychotropic
4. Australian Medicines Handbook
5. NPS MedicineWise — anticholinergic burden
6. TGA — Citalopram/escitalopram QTc alert 2011
7. AIHW — Suicide and self-harm monitoring
8. Alexopoulos — Depression in the elderly (Lancet 2005)
9. Wilson — Cochrane antidepressants in elderly (2013)
10. Cipriani — antidepressant NMA (Lancet 2018)
11. Kellner — ECT in late-life depression (Am J Psychiatry 2016)
12. Beyond Blue — older Australians
13. My Aged Care
14. HealthDirect — Depression